Member Info for Doc.Daneeka

But thanks I'll gladly take your advice

Manifesto I think I prefered you when you were Tommy's lapdog

Pointless to continue this Mani. It's not good for you and of no use to the board. Whether you think they need to start in Q1 is not the issue. They will start when they're ready and although there's no evidence at all that they're ready for Q1 - there's no evidence that they're not. We'll know when it starts most likely and as we can't do a thing to alter it, we just wait.

Td will always have the last word so the only way to stop the endless thread is to let him have it - or filter him. Either way let's move on.

Professional's cynicism about the board's motives is noit my view. They're still doing their best and still have a chance of success. They won't keep the company whatever happens but they may see the drug successfully through to a couple of meaningful P3s and if they do this - with the diagnostics in place - the drug won't fail.

" No News Before March!!!! " March is entirely likely Mani and no reason for hysterics. It's 9 weeks away. Q2 is more likely as a start now I think, and as i posted yesterday - that's ok. Long as the trials are perfectly designed and they can somehow limp over the finish line. RM will give us a steer in 10 days. Let's wait for that

And I've filtered him again so he may answer as he wishes - but I won't be looking at it. Hoping this will contribute a small measure to the spirit of goodwill we should all be fostering as Father Christmas gets ready for his rounds.

The Chinese have developed IfN 1 nasal sprays and demonstrated prophylactic and therapeutic use during the pandemic. They've also trialed it with other respiratory diseases - with good results. It's not an area in which SNG has any stake or data. And at £3000 a pop and with limited and/or unknown continued action it's pretty clear that SNG as it is currently formulated and delivered will never be of use prior to infection or in early infection.

Given that Synairgen is now preparing trials exclusively set in hospital and ICU this statement is not supportive.

"timely and potent IFN-Is production (18–24 h post-infection) promotes both innate and acquired immune responses, whereas delayed IFN-Is production (3–4 days post-infection) actually contributes to ineffective anti-infection as well as excessive inflammation "

Always grateful for the steady daily, and sometimes hourly stream of links and supportive evidence posted by Td - and pleased to see that he's not only aware that there is also contrary evidence, but is also prepared to share this with the board.

Thanks TP To be fair to the company - they have had real work to do on the diagnostics and on trial design. First time since the lead up to Sprinter that they've been fully engaged in real science ( discounting but without insult the analysis of P3 and COPD data that's been done successfully ) This is blue sky territory for the company. They can't change the drug, or afford to play around with dosing or dosing periods but they have to find the exact cohort of patients who will benefit - using new technology and hopefully making use of the best brains in the company. This is nothing to do with RM and I hope he's sitting in his office looking at the Solent - but hopefully a process led by PM and with input from the bods at Southampton Uni, Janssen and perhaps Casanova labs and some AI specialists. Designing multiple trials across different Respiratory diseases. The most difficult thing they've attempted since Sprinter - and with just one shot at the bull.

If they're nearly ready with all of this, RM's New Year message will be upbeat and may hint that the start is imminent and perhaps expalin something about the work. If they're still looking through microscopes at samples, running tests, and scratching their heads - he'll be more circumspect and we might then expect a Q2 start.

As many have said, when they start only matters if they run out of money. But they are not rushing, as it is the only bullet in the gun and this time spent getting the diagnostics absolutely spot on is well spent. I've accepted the loss of my investment and don't expect to get much back - but I'd still love this project to end in lives saved, and I still believe it can.

No - you dragged him in to this thread Tommy. Let's all ask ourselves if any one poster on this board behaves as if they have a direct financial stake in relentless positivity, or negativity for that matter. We have the self confessed traders and fanboys like Fruits - but there's only one Td and he's most definitely on someone's payroll. Never seen before Feb 2022 - and now never absent.

Tommyd brought your name up Fruits - have a word with him. Make a stern Paddington stare will do it

Ok fair enough - if you're saying they'll add in a few extra that the consultant identifies as serial offenders.

“Universal - 300 odd samples already taken and in freezer. These will be studied and used for analysis. Not waiting for any more patients/samples”

I posted this yesterday "SNG has the data from the first 300 UNIVERSAL patients and is not waiting for the trial to end " mostly in response to Aether's fear that they might have to wait for UNIVERSAL to end.

Thanks Jint. I wasn't contesting the open label aspect. If RM made that statement he had no right to do so, as it goes against everything we've been told about the way the next set of patients will be chosen. "frequent attendance of A&E with a confirmed respiratory infection " could be an inclusion criteria I suppose - but it's highly unlikely.

What matters is the number of hospitals - not whether the trials are multi-national. If the trial opens at 4 locations in the UK and 2 in the States it'll still take a while to find the patients.

Let's hope they are ready to go in the first 1/4 of 2024. Catch the tail of this season and fill the trials sometime after that - and hopefully before another year elapses

Tommyd you've been rumbled mate. No other shares - posting on no other board except this one - very often supported by links to absolutely anything that might be supportive. You go on about derampers ( as if there's anything to deramp at 7p ) and yet you spend hours every day either responding to what you preceive as negativity, and what the rest of us see as realism, or trawling the internet for the latest ifn mouse model.

I'll leave it there. Maybe others can express a view. The original intent in launching both UNIVERSAL and our P2s was clearly to catch the winter respiratory season. If Fruits and Tommyd dispute this then there's nothing more to say to them. UNIVERSAL can continue recruiting year round as the entry criteria is just a positive test for a rspiratory infection - which ought to be almost everyone admitted at any time of year. Inclusion on the P2s will be much much more precise and will need the much sicker winter season patients - whether in 23/24 or 24/25.

The maths is not simple. SNG will work to the level required in just a fraction of those admitted to ICU. And breathlessness - use of supplementary oxygen - the old metrics used in previous SNG trials are not good enough. They need to show an effect in every patient dosed. That's why we're waiting for the UNIVERSAL data to be turned into the diagnostic tools required to find the exact cohort required.

If Synairgen had the cash these would be large P3s and they could afford to have a few patients show no effect.

Second point is that we have no idea how many hospitals the P2s will open at. Because of cash constraints we're likely to be back to the very small number used for SGO16 - and if that's the case the trials will fill slowly.

Universal tests patients to confirm a respiratory infection. And then they're admitted to the trial.A very basic entry requirement. Synairgen's P2s need to test people and confirm they will benefit specifically from SNG based on the much more refined criteria which we all read on here frequently. They'll need to test many more than the 30-50 required to find the correct cohort and get the trials underway.

Fruits desn't even need to get out of bed. Td reposts for him. What's relevant in the two long cut and pastes is that despite a year long flow of patients there really IS a respiratory disease season "Nationally, prepandemic seasons (2017–2020) began in October, peaked in December, and ended in April. "

Covid may have something more to say about this in the coming peak months but to deny that these outbreaks are seasonal is disingenuous in the extreme

The second cut and paste includes this unattributed quote

“These trials will also include open label approach, where the intervention is not run on an randomised basis, against placebo product but on open label, where the trial data can be studied on the go - and because of the targets, such patients are already known to clinicians as they are regulars each virus season - ie they are repeat visitors. So the chances of the wrong patients, wrong therapy in those tight target populations are virtually eliminated”

Presumably from the q and a at the AGM or in the pub chat afterwards.

Clearly wherever this emanated - it's nonsense. If it was the case that the regulars who trot up to A&E wheezing and spluttering each winter will make patient selection a slam dunk - then wtf are they doing spending all this time trying to create the diagnostic tools to identify the cohort needed.

This sentence is just ridiculous "So the chances of the wrong patients, wrong therapy in those tight target populations are virtually eliminated "

We know that the only way mini P2s of 30-50 patients can succeed is in using the new and sophisticated diagnostic suite - they will not work by senior clinicians saying - " this one will do - he's in here every year "

But SNG has the data from the first 300 UNIVERSAL patients and is not waiting for the trial to end. The timeline is P2 trials to begin before the end of H1 2024. If they start early in the new year - which must be unlikely - they might finish in H1 as they'll catch the winter Respiratory disease season. If they don't catch it, they'll probably still be recruiting patients this time next year.

Mani it doesn't matter if you or I or anyone else is concerned about cash burn. It is what it is and all we can do is wait and hope that whatever they are designing works and is complete before the money runs out. I hoped we'd have the protocols before the end of year, but that hasn't happened. I'm confident SNG is not a turkey - but it's certain that LTHs will still get stuffed.

The P2s are still binary. Nobody except us will care that they're underway - and the sp won't move ( unless the RNS comes after a significant extra release of data from UNIVERSAL, which shows they really do know how to identify the patients )

Sorry - and finally Mani - that's why UNIVERSAL is so important. If it helps them develop the diagnostic tools to find the right triallists